ReviewCureus2025
The C-reactive Protein-Albumin-Lymphocyte Index Predicts Survival Outcomes in Esophageal Cancer: A Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte Index in Hepatobiliary and Pancreatic Cancers: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Prediction of anastomotic leakage after esophagectomy for esophageal cancer: a nomogram study integrating systemic inflammation indices and clinical factors.Frontiers in oncology · 2026Article
- Association and incremental predictive value of preoperative AISI and CALLY for postoperative pulmonary complications after McKeown esophagectomy following neoadjuvant chemoimmunotherapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The C-reactive protein-albumin-lymphocyte (CALLY) index represents a novel composite biomarker integrating systemic inflammation, nutritional status, and immune function. This systematic review and meta-analysis aimed to evaluate the prognostic significance of the CALLY index in esophageal cancer patients. A comprehensive literature search was conducted across multiple databases from inception to August 2025, identifying studies that investigated the association between the CALLY index and survival outcomes in histologically confirmed esophageal cancer patients. The majority of studies employed retrospective cohort designs, with three being single-center studies and two utilizing multi-center approaches. The studies were conducted between 2024 and 2025, with four originating from Asian populations and one from a Western population. Meta-analysis revealed that patients with higher CALLY index values experienced significantly better overall survival compared to those with lower values (risk ratio (RR): 2.24, 95% CI: 1.71-2.94, p<0.001), despite moderate heterogeneity (I²=62%). Similarly, a higher CALLY index was associated with improved disease-free survival (RR: 1.99, 95% CI: 1.65-2.40, p<0.001) with no heterogeneity observed (I²=0%). Sensitivity analyses confirmed the robustness of these findings. The CALLY index demonstrates significant prognostic value in esophageal cancer, with lower values indicating worse outcomes. This composite biomarker may serve as a valuable tool for risk stratification and treatment planning, potentially guiding personalized therapeutic approaches. However, standardization of cut-off values and validation through prospective studies are needed to establish its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.